These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity. Kulkarni-Munje A; Palkar S; Shrivastava S; Lalwani S; Mishra AC; Arankalle VA Immun Inflamm Dis; 2021 Jun; 9(2):419-434. PubMed ID: 33452858 [TBL] [Abstract][Full Text] [Related]
18. Unique immunological profile in patients with COVID-19. Varchetta S; Mele D; Oliviero B; Mantovani S; Ludovisi S; Cerino A; Bruno R; Castelli A; Mosconi M; Vecchia M; Roda S; Sachs M; Klersy C; Mondelli MU Cell Mol Immunol; 2021 Mar; 18(3):604-612. PubMed ID: 33060840 [TBL] [Abstract][Full Text] [Related]
19. Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8 Roukens AHE; Pothast CR; König M; Huisman W; Dalebout T; Tak T; Azimi S; Kruize Y; Hagedoorn RS; Zlei M; Staal FJT; de Bie FJ; van Dongen JJM; Arbous SM; Zhang JLH; Verheij M; Prins C; van der Does AM; Hiemstra PS; de Vries JJC; Janse JJ; Roestenberg M; Myeni SK; Kikkert M; Yazdanbakhsh M; Heemskerk MHM; Smits HH; Jochems SP; ; Nat Immunol; 2022 Jan; 23(1):23-32. PubMed ID: 34937933 [TBL] [Abstract][Full Text] [Related]
20. Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients. Kos I; Balensiefer B; Lesan V; Kaddu-Mulindwa D; Thurner L; Christofyllakis K; Bittenbring JT; Ahlgrimm M; Seiffert M; Wagenpfeil S; Bewarder Y; Neumann F; Rixecker T; Smola S; Link A; Krawczyk M; Lammert F; Lepper PM; Bals R; Stilgenbauer S; Bewarder M Eur J Immunol; 2021 Jun; 51(6):1449-1460. PubMed ID: 33788264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]